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Abstract
Introduction A conservative treatment strategy is often
proposed as a primary treatment option in the management
of vestibular schwannomas (VS). In this “wait and scan”
policy, audiovestibular symptoms are monitored regularly,
and VS growth is measured on consecutive magnetic
resonance images (MRI). The aim of this study is validation
of two-dimensional versus volume MRI assessment in the
longitudinal follow-up of VS and to define tumor growth
beyond measurement error.
Methods MRI scans of 68 consecutive patients with VS
were analyzed retrospectively. Two-dimensional and vol-
ume measurements on contrast enhanced (CE) T1- and T2-
weighted images were performed independently by two
readers. Smallest detectable differences (SDD) were calcu-
lated, and intraclass correlation coefficients (ICCs) were
determined for both assessment methods.
Results Two-dimensional and volume measurements both
showed best reproducibility on CE T1-weighted images.
SDD for differences relative to baseline MRI [SDD (%)]
for two-dimensional measurements had a higher interob-
server error compared to volume measurements (40%
versus 19.7%), which decreases when tumor size
increases. The ICC for two-dimensional measurements
in three directions was 0.947, 0.974, and 0.978 and for
volume measurements 0.999.
Conclusion Volume measurements are more accurate com-
pared to two-dimensional measurements for the evaluation
of VS growth. These measurements are assessed preferably
on CE T1-weighted images. SDD (%) strongly depends on
VS size. SDD between consecutive scans exceeds the
common clinical applied criterion of 1 or 2 mm growth to
define growth.
Keywords Vestibularschwannoma.Magneticresonance
imaging.Validity.Volumemeasurement
Introduction
The wide availability and technical improvement of magnetic
resonanceimaging(MRI)hasledtoanincreaseindetectionof
vestibular schwannoma (VS) at an early stage [1]. Accord-
ingly, the incidence of diagnosed VS has increased [2, 3].
The natural development of VS remains uncertain as growth
percentages between 30% and 90% have been reported,
depending at least in part on the length of the observation
period [2, 4]. So far, no clinical parameters have been
identified to correlate with VS growth [5–7], and therefore,
VS growth is objectified by performing consecutive MRI
[2, 5]. If growth is found on MRI, an intervention may be
chosen, such as surgical resection or radiation therapy [6, 8].
Most patients therefore enter the so-called wait and scan
policy for a certain period, in which the audiovestibular
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Radiologists generally use two-dimensional measure-
ments to assess VS growth, although volume measurements
seem to provide more accurate growth assessment [1, 9, 10]
since VS shows asymmetric growth in all directions. Little
information is published about the diameter increase or
volume increment between subsequent images that consti-
tute to VS growth beyond measurement error [9–12].
Usually, when an increase in tumor diameter or volume is
found, it is considered to be growing, but validation of this
observation is lacking. Especially when invasive treatment
decisions are based on these observations, it is of great
importance to find the most suitable method to assess
growth of VS on MRI and to provide a definition of growth
beyond measurement error.
This study focuses on the accuracy and reproducibility
of VS volume measurements compared to two-dimensional
measurements to determine VS growth on MRI. The
hypothesis is that measurement of tumor volume with
specific area tracing software is a more accurate tool
compared to two-dimensional measurements for determin-
ing tumor growth.
Materials and methods
AllpatientswhoreceivedanMRIscanofthecerebellopontine
angle (CPA) between January 2003 and March 2008 in our
tertiary referral center were analyzed retrospectively. Patients
were included in this study if a radiological diagnosis of a VS
was made, resulting in 102 patients. Thirty patients were
excluded who had been treated by surgery or radiotherapy,
resulting in 72 patients. Four patients who had an intra-
labyrinthine schwannoma were also excluded. There were no
patients with neurofibromatosis type 2. MRI images of 68
patients, 32 (47%) men and 36 (53%) women, age range of
36–84 years, median age of 63.5 years, were available; one
scan was available in 21 patients, two scans were available in
22 patients, three scans in ten patients, four scans in eight
patients, five scans in four patients, and six scans in three
patients, resulting in a total of 165 scans suitable for analysis.
In patients with more than one scan, mean follow-up was
21.8 months (SD 15.7).
All examinations were performed at 1.5 T (Gyroscan,
Powertrack 6000, Philips, Best, The Netherlands) using a
head–neck coil (Philips, Best, The Netherlands). The MR
protocol consisted of axial 2D SE T1-weighted images
(TR/TE, 550/15 ms; slice thickness, 3 mm; inter slice gap,
0.3 mm; number of slices, 12;FOV, 180 mm (RFOV 80%);
and matrix 256×256), axial 3D TSE T2-weighted images
(TR/TE, 3,000/250 ms; slice thickness, 0.35 mm; number
of overcontiguous slices ,30; FOV, 130 mm (RFOV 80%),
and matrix 256×256) covering the skull base, and contrast-
enhanced (gadolinium 0.2 ml/kg body weight) axial 3D
ISO T1-weighted images (TR/TE, 8.9/4.6 ms; slice thick-
ness, 1 mm; FOV, 256 (RFOV 80%); and matrix 256×256)
covering the entire skull base and cranium. All patients
underwent the same MRI protocol with similar parameters
and planes of acquisition to ascertain an optimal correlation
in serial scans.
Two readers, experienced in head and neck imaging,
independently performed the measurements on contrast-
enhanced T1-weighted images (CE T1-WI) and on the
corresponding T2-weighted images (T2-WI). Both observ-
ers were blinded to each other’s MR assessments and
clinical information.
For two-dimensional assessment of VS, the maximum
diameter was measured in three diameters: anteroposterior
(AP), mediolateral (ML) [including the portion in the
internal auditory canal (IAC)], and craniocaudal (CC)
(Fig. 1a, b). To establish these dimensions, a digital
submillimeter ruler was used. Volume assessment was done
on a stereotactic radiotherapy treatment planning station,
fitted with iPlan® RT image version 3—Advanced Con-
touring Workstation (BrainLAB Oncology Solutions, Feld-
kirchen, Germany). MR images were uploaded in this
system, and area tracing software was used to outline the
VS on each MR image that contained tumor tissue
(Fig. 2a). If there was a sharp contrast with surrounding
F i g1a , b Contrast-enhanced
T1-weighted image with a ves-
tibular schwannoma in the cere-
bellopontine angle (CPA) on the
right side. a Measurements in the
axial plane: X is the maximum
mediolateral, and Y the maxi-
mum anteroposterior dimension;
b in the coronal plane, the Z
demonstrates the maximum cra-
niocaudal dimension
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automatically) was used. Manual segmentation was neces-
sary in cases in which differentiation with surrounding
tissue was difficult because of the high sensitivity of this
autotracer. Each segmentation result was checked visually.
By tracing the VS surface on all slices, the software was
able to calculate VS volume (Fig. 2b). Volumetric analysis
was expressed in cubic centimeter.
To compare reproducibility of the measurements in
different size categories, VS were classified into four
stages, as defined by Hasegawa et al. [13]: stage A,
intracanalicular VS; stage B, VS extending into the CPA;
stage C, VS compressing the brain stem; and stage D, VS
deviating the fourth ventricle.
Statistical analysis
Reproducibility measures consist of agreement and reliabil-
ity parameters [14]. These parameters were evaluated for
measurements by two different readers at one point in time.
SPSS 15.0 statistical software (SPSS, Chicago, Il, USA)
was used to perform the statistical calculations. For
evaluation of interobserver reproducibility, we used base-
line measurements of the MRI scans from the 68 patients
for both readers, which can be considered as independent
observations, whereas consecutive measurements within
patients are correlated.
Agreement parameters
Agreement parameters measure the ability to achieve the
same value in two measurements and give an indication of
the size of measurement errors [14]. The agreement
between two readers was evaluated using Bland and
Altman plots [15]. The Bland and Altman plot is the most
robust method to quantify agreement in clinical measure-
ments. Here, the differences between measurements (on the
Y-axis) are plotted against the mean of two measurements
(on the X-axis). The visual representation of agreement
illustrates the magnitude and range of the differences, bias
or outliers, and the relation between the magnitude of the
differences and the magnitude of the mean values [15]. This
method also assesses 95% limits of agreement. These limits
of agreement are used to define the smallest detectable
difference (SDD) as 1.96×the standard deviation (SD) of
the mean difference in measurements between the two
readers. SDD represents the change that can be detected
beyond measurement error [15]. We can define a tumor to
have grown when the difference between two measure-
ments falls outside this interval. In this way, it will be
possible to discriminate between stable tumors and growing
tumors, according to our measurements. For both two-
dimensional and volume measurements, the SDD for
absolute differences and for differences relative to baseline
[SDD (%)] was calculated. Differences relative to baseline
were calculated using the following formula: (A−B)/
[(A+B)/2]×100, in which A is the result of reader A and
B the result of reader B. The SDD and SDD (%) were
presented for four VS stages: A, B, C, and D.
Use of the SDD (%) enables comparison of the different
unities involved in the two different measurement techni-
ques (millimeter and cubic centimeter). Because, in clinical
practice, all three diameter measurements (CC, AP, and
ML) are equally essential in assessing VS progression, we
considered the diameter with lowest agreement as the
limiting factor in diameter measurements. We compared
the SDD (%) of this diameter with the SDD (%) of volume
measurements.
Fig. 2 a: Example of area tracing with volume software. Axial
contrast-enhanced T1-weighted image shows a right-sided vestibular
schwannoma (asterisk) with a large cerebellopontine angle compo-
nent. The red line is the result of the autotracer which lines the
vestibular schwannoma. b Three dimensional representation of a
vestibular schwannoma (VS), integrating the surface of all slice
intervals. The small intracanalicular (A) and large extracanalicular (B)
portion of the VS can easily be identified
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Reliability parameters assess whether measurements can be
used to distinguish patients from each other despite
measurement error [14]. A parameter of reliability is the
intraclass correlation coefficient (ICC). The ICCs are
defined as the ratio of the variance among patients (patients
variability) over the total variance (among patients, among
readers, plus the error variance), which is expressed as a
dimensionless number, being one (perfect reliability) in the
most ideal case. ICC was calculated for interobserver
diameter and volume VS measurement and was also
presented for four VS stages: A, B, C, and D.
Results
Bland and Altman plots were constructed using data of the
baseline MR images of the 165 scans from 68 patients
(Figs. 3 and 4). The SD for each reader (A and B) and the
SD of the mean difference between readers are presented in
Table 1. The SDD and SDD (%) for absolute differences
and differences relative to baseline MR images, respective-
ly, are presented in Table 2. In Table 3, we present the ICC
with 95% confidence intervals.
Contrast-enhanced T1- versus T2-weighted images
Two-dimensional and volume assessments of VS were
performed on both CE T1-WI (CC dimension, T1CC; AP
dimension, T1AP; ML dimension, T1ML; volume,
T1VOL) and T2-WI (CC dimension, T2CC; AP dimension,
T2AP; ML dimension, T2ML; volume, T2VOL). The
dimension with highest SDD (%) was taken as a limiting
factor, when comparing both imaging modalities.
With two dimensional measurements, the SDD (%) for
T1CC appeared to be equal to T2CC (40.3 and 40.1)
However, the T2AP dimension showed higher SDD (%)
compared to T1AP: 34.3 versus 28.3, respectively. There-
fore, CE T1-WI showed highest agreement in two dimen-
sional measurements. In addition, the ICC was consistently
higher in T1CC, T1AP, and T1ML directions, compared to
T2CC, T2AP, and T2ML directions (0.947, 0.974, and
0.978 versus 0.943, 0.961, and 0.948), reflecting higher
reliability for CE T1-WI in two-dimensional measurements.
For volume measurements, similar results were obtained:
SDD (%) for T1VOL was 19.7 compared to 30.1 in
T2VOL. ICC values for volume measurements for both
sequences were 0.999.
Volume measurements versus two-dimensional
measurements
The SDD (%) values for T1CC, T1AP, and T1ML were
40.3, 28.3, and 20.9, respectively (Table 2). All three
dimensions are equally essential in estimating VS growth.
Because the T1CC dimension is the limiting factor in
these two-dimensional measurements, with its lowest
agreement, it was used to compare the two-dimensional
measurements with volume measurements. The SDD (%)
Fig. 3 Bland and Altman plot of baseline two-dimensional maximum
craniocaudal (CC) dimension measurements on contrast-enhanced T1-
weighted images (CE T1-WI). The values on the Y-axis represent the
measurement differences between the two readers and their mean
difference (thin line). The values on the X-axis represent the mean of both
measurements. The thick black lines represent the 95% limits of agreement.
Interobserver differences are larger in smaller vestibular schwannomas
Fig. 4 Bland and Altman plot of baseline volume measurements on
contrast-enhanced T1-weighted images (CE T1-WI). The values on
the Y-axis represent the measurement differences between the two
readers and their mean difference (thin line). The values on the X-axis
represent the mean of both measurements. The thick black lines
represent the 95% limits of agreement. Interobserver differences are
larger in smaller vestibular schwannomas
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volume measurements (T1VOL): 40.3% versus 19.7%.
The SDD (%) decreased with increasing tumor size from
stage A to type D VS, in both two-dimensional and in
volume measurements (Table 2). In all tumor stages,
volume measurements were associated with smaller SDD
(%) compared to CC dimensional measurements. The ICC
revealed that both two-dimensional and volume measure-
ments showed high interobserver reliability. However,
volume measurements revealed a higher reliability com-
pared to the three diameter measurements (0.999 versus
0.947, 0.974 and 0.978). Reliability increased with tumor
size, and volume measurements were more reliable in all
VS stages (Table 3).
Table 1 Interobserver agreement parameters based on baseline T1-weighted, contrast-enhanced images (CE T1-WI) and T2-weighted images in
68 patients.
Baseline Two-dimensional measurements on CE T1-WI (mm) Volume measurements on CE T1-WI (cm
3)
CC AP ML VOL
Reader A, mean (SD) 8.40 (4.60) 8.70 (4.90) 12.70 (5.70) 0.85 (1.74)
A( n=29) 5.00 5.06 8.32 0.13
B( n=27) 9.05 9.71 14.28 0.63
C( n=6) 12.58 12.23 18.12 1.29
D( n=6) 17.50 18.33 21.62 4.71
Reader B, mean (SD) 8.20 (4.80) 8.60 (5.10) 13.20 (5.70) 0.81 (1.69)
A( n=29) 4.59 5.03 8.58 0.13
B( n=27) 9.27 9.86 15.06 0.63
C( n=6) 11.53 13.10 18.28 1.06
D( n=6) 18.33 18.93 22.28 4.57
Meandiff (SDdiff) 0.12 (1.53) -0.18 (1.14) -0.48 (1.08) 0.01 (0.055)
Baseline Two-dimensional measurements on T2-WI (mm) Volume measurements on T2-WI (cm3)
CC AP ML VOL
Reader A, mean (SD) (n=68) 7.60 (4.5) 8.20 (5.00) 11.90 (5.50) 0.72 (1.49)
Reader B, mean (SD) (n=68) 7.20 (4.00) 8.40 (4.90) 12.10 (5.00) 0.72 (1.50)
Meandiff (SDdiff) 0.35 (1.41) −0.18 (1.37) −0.21 (1.69) 0.07 (0.069)
The rows of reader A and B of each imaging modality present the means and standard deviations of the measurements assessed by these readers.
The means and standard deviations are also subdivided according to vestibular schwannoma stage for CE T1-WI. The mean difference row
presents the mean differences between the measurements of reader A and B and the SD of these differences
A intracanalicular, B extracanalicular, C compressing brain stem, D deviating fourth ventricle, SD standard deviation, CC craniocaudal dimension,
AP anteroposterior dimension, ML mediolateral dimension, VOL volume, Meandiff mean of the observer difference, SDdiff standard deviation of the
differences between observer A and B, CE T1-WI contrast enhanced T1-weighted images, T2-WI T2-weighted images
Table 2 SDD and SDD (%) for measurements performed on T1-weighted, contrast-enhanced (CE T1-WI) images and T2-weighted images.
CC CC AP AP ML ML VOL VOL
SDD (mm) SDD (%) SDD (mm) SDD (%) SDD (mm) SDD (%) SDD (cm
3) SDD (%)
T1 A–D( n=68) 2.98 40.3 2.23 28.3 2.12 20.9 0.11 19.7
T2 A–D( n=68) 2.76 40.1 2.69 34.3 2.69 30.52 0.14 30.1
T1 A (n=29) 2.41 52.8 1.49 28.0 1.96 27.1 0.05 28.9
T1 B (n=27) 3.23 34.5 2.53 26.5 2.33 17.8 0.06 10.4
T1 C (n=6) 3.60 32.7 3.05 28.7 2.49 14.9 0.07 8.70
T1 D (n=6) 2.96 18.8 2.90 23.7 1.08 5.00 0.26 5.70
The SDD and SDD(%) for CE T1-WI are subdivided according to vestibular schwannoma (VS) stage: A intracanalicular VS, B VS extending into
the cerebellopontine angle, C VS compressing brain stem, D VS deviating the fourth ventricle
SDD smallest detectable difference, SDD (%) smallest detectable difference relative to baseline measurements, CC craniocaudal dimension, AP
anteroposterior dimension, ML mediolateral dimension, VOL volume
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and volume measurements
SDD for two dimensional measurements on CE T1-WI
varied from 2.12 to 2.98 mm. For volume measurements on
CE T1-WI, SDD was 0.11 cm
3 (Table 2).
Discussion
VS are benign neoplasms, originating from the neurolemnal
sheath of the eighth cranial nerve and are predominantly
found in the CPA and in the internal auditory canal (IAC).
The incidence of VS varies from 1 to 2/100,000 [2, 12, 16,
17], although postmortem histopathological examinations
show a higher incidence of about 2.7% [18]. This
discrepancy indicates that the vast majority of VS never
become symptomatic, reflecting very slow or arrested
growth.
Therefore, the wait and scan policy has gained popular-
ity as an alternative or prelude to surgery and radiation
therapy. This can be justified, as growth is known to be
extremely variable with most VS remaining stable or
showing minimal growth for many years [16, 19]. The
goal of this regimen is to minimize therapeutic risks and
complications and to preserve an optimal quality of life in
selected patients. Because no single reliable clinical feature
exists that predicts tumor growth [5–7], MRI is the
mainstay in the conservative management of VS [2, 5]. It
is essential to use a measuring method that provides reliable
measurements with a high interobserver agreement, as
change in size is—besides its clinical presentation—the
most relevant parameter.
Various ways of describing VS tumor growth have been
proposed. The conventional method of assessing VS is by
performing two-dimensional measurements. Some authors
use the largest AP and/or ML dimension, sometimes
combined with the CC dimension [5, 8, 19–24]. Others use
the guidelines for measuring VS described by the American
Academy of Otolaryngology, Head and Neck Surgery
(AAO-HNS) [6, 7, 25]. The usefulness of two-dimensional
measurements could be doubted. Firstly, two-dimensional
measurements assesses VS growth in maximal three direc-
tions, while a VS shows asymmetric growth in all possible
directions; therefore, a two-dimensional assessment does not
approach “real” tumor growth. Secondly, in VS with large
diameters, a small increase in diameter corresponds to a
much larger increase in VS volume than a similar increase in
diameter in a small VS [1]. Volume measurements can be
performed in several ways; some authors consider VS to be
ellipsoid and calculate the volume using a mathematical
formula [11, 21, 26, 27]. However, this method has shown to
produce a large overestimation of VS volume [1, 11]. Others
have performed true volumetric measurements by using
(semi)automatic software to calculate VS volume [1, 9, 11,
12, 21, 28, 29]. According to the few studies comparing two-
dimensional versus non-formula-based volume measure-
ments, the VS volume measurements are more accurate
compared to two-dimensional measurements [1, 9, 10].
Other authors disagree with this [16, 21, 27], and also in
clinical practice, most clinicians keep relying on two-
dimensional measurements. However, the results of this
study indicate that VS volume measurements, especially on
the CE T1-WI, produce a better interobserver agreement and
reliability compared to the two-dimensional measurements.
This study therefore indicates that CE T1-WI volume
measurements should replace two-dimensional measure-
ments in evaluating VS growth. The difference in interob-
server agreement and reliability between the two
measurement methods is of clinical significance because
invasive treatment decisions are based on these observations.
Therefore, the measurement method with highest agreement
on reliability is necessary in assessing VS growth.
An exception may be made concerning small (stage A)
VS. In these small intracanalicular VS, the CC dimension
does not play an important role, since the diameter of the
Table 3 Intraclass correlation coefficients (ICC) for two-dimensional and volume measurements on T1-weighted, contrast-enhanced images (CE
T1-WI) and T2-weighted images with their 95% confidence intervals.
CC AP ML VOL
T1 A–D 0.947 (0.915–0.967) 0.974 (0.957–0.984) 0.978 (0.965–0.987) 0.999 (0.999–1.000)
T2 A–D 0.943 (0.909–0.965) 0.961 (0.938–0.976) 0.948 (0.917–0.968) 0.999 (0.998–0.999)
T1A (n=29) 0.564 (0.260–0.768) 0.862 (0.729–0.932) 0.947 (0.892–0.975) 0.987 (0.973–0.994)
T1B (n=27) 0.674 (0.393–0.841) 0.802 (0.604–0.907) 0.889 (0.767–0.949) 0.988 (0.973–0.994)
T1C (n=6) 0.840 (0.315–0.975) 0.917 (0.588–0.988) 0.968 (0.822–0.995) 0.999 (0.993–1.000)
T1D (n=6) 0.966 (0.810–0.995) 0.980 (0.883–0.997) 0.990 (0.942–0.999) 0.999 (0.992–1.000)
ICC values for CE T1-WI are subdivided per VS stage: A intracanalicular VS, B VS extending into the cerebellopontine angle, C VS compressing
brain stem, D VS deviating the fourth ventricle
CC craniocaudal dimension, AP anteroposterior dimension, ML mediolateral dimension, VOL volume
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HNS guidelines, the CC direction is not taken into account
at all. Then, the AP direction is the limiting factor of the
remaining AP and ML directions (Table 2). In stage AVS,
under these conditions, we found that measurement error
[SDD(%)] of both two-dimensional and volume measure-
ment techniques are comparable (AP 28.0, ML 27.1, and
VOL 28.9). Therefore, both measurement techniques can be
used to evaluate stage AVS. In larger VS (stages B and C),
both AP and ML dimensions show higher measurement
error [SDD (%)] compared to volume measurements. In
stage D VS, the SDD (%) of the ML dimension equals the
SDD (%) of volume measurements: 5 versus 5.7, respec-
tively. This can be explained by the fact that the ML
dimension is the longest distance in two-dimensional VS
measurements, and measurement error will decrease when
measurement distances increase. This occurs both in two-
dimensional and in volume measurements and should be
taken into account when evaluating growth in different VS
stages (Table 2 and Figs. 3 and 4). Other authors confirm
this phenomenon [1, 11, 30]. However, apart from this low
SDD (%) of the ML dimension in stage D VS, the far worse
SDD (%) of the AP dimension should also be taken into
account in evaluating VS growth with two-dimensional
measurements, thus pleading for the use of volume
measurements in the assessment of stage B, C, and D VS.
Overall, contrast-enhanced images are necessary, both in
volume and two-dimensional measurements, to maintain a
high reproducibility, since it facilitates differentiation of VS
from surrounding tissue.
The calculated agreement [SDD and SDD (%)] and
reliability (ICC) values were compared with findings
reported in the literature. Studies addressing the change in
length and volume exceeding measurement error (SDD) are
reported inconclusively. In two-dimensional VS measure-
ments, many authors simply state a 1- or 2-mm increase in
subsequent scans as evidence of growth without any
statistical justification [2, 6–8, 20, 22, 31]. According to
this present study, SDD varies between 2.12 mm for the
ML dimension and 2.98 mm for the CC dimension on CE
T1-WI (Table 2). This indicates that there is a measurement
error in two-dimensional measurements, which is not
recognized when a measured increase in size of only 1 or
2 mm between follow-up scans is considered as tumor
growth, and treatment decisions should be used with
caution when using these arbitrary criteria.
In volume measurements, an absolute increase above
which one can consider a VS to have grown was not found
in the literature. This study revealed SDD ranging from
0.05 to 0.26 cm
3 (types A–D) on CE T1-WI (Table 2).
Volume increase expressed as SDD (%) varied from 15 to
89% in the literature [9–12]. However, the numbers of
patients in these studies were small [9, 11, 12], and
generally, not only baseline measurements of the VS were
taken into account [9, 10, 12]. Therefore, the percentages
reported in the literature could be questioned. In this study,
SDD (%) in CE T1-WI volume measurements was 19.7%.
ICC for two-dimensional measurements was not found in
the literature. One study calculated ICC for volume
measurements: Luppino et al. [9] calculated ICC for two
different types of volume measurement. Their “contour
method,” similar to our volume method, had an interob-
server reliability of 0.96, which is comparable to the ICC of
0.99 in this study.
This study and technique also harbor some limitations.
Firstly, the assessments of reproducibility parameters were
based on interobserver differences and not on intraobserver
differences. It was assumed that this approach better reflects
clinical practice, where it is usual that different clinicians
assess subsequent scans.
Secondly, BrainLAB volume software is not widely
available in radiology departments
Thirdly, performing these volume measurements takes a
little more time compared to the conventional two-
dimensional measurements. In our experience, VS contour-
ing and volume calculation typically took a few minutes.
This could be a limiting factor in introducing this method
for VS in daily clinical practice. In the literature, 10–25 min
for manual segmentation has been described, although these
calculations were performed with different software and on
older systems [10, 11].
Fourthly, the used volume measurement method is semi-
automatic. However, there is still a human component that
is responsible for an interobserver difference. It is desirable
to develop software able to perform even better automated
volume measurements in order to further diminish reader-
related measurement error.
Conclusion
CE T1-WI volume measurements show better interobserver
agreement and reliability compared to two-dimensional
measurements for the assessment of growth of VS. Small
intracanalicular VS form an exception. When evaluating
VS growth, one has to take VS baseline characteristics into
account because SDD (%) strongly depends on VS size.
The 1- or 2-mm difference commonly used to define
growth of VS in consecutive scans in two-dimensional
measurements lies within measurement error and should not
direct clinical practice.
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